FOLLOWUS
1.Academy of Integrative Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou (350122), China
2.Chen Keji Academic Thought Inheritance Studio, Fujian University of Traditional Chinese Medicine, Fuzhou (350122), China
3.Fujian Key Laboratory of Integrative Medicine on Geriatrics, Fujian University of Traditional Chinese Medicine, Fuzhou (350122), China
4.The Third People's Hospital Affiliated to Fujian University of Traditional Chinese Medicine, Fuzhou (350122), China
5.Department of Research and Development, Youcare Pharmaceutical Group Co., Ltd., Beijing (100176), China
Dr. CHU Jian-feng, E-mail: jianfengchu@126.com
纸质出版日期:2021-06-01,
网络出版日期:2020-12-22,
录用日期:2020-06-16
Scan for full text
Mei-zhong PENG, Mei-ling YANG, A-ling SHEN, 等. Huoxin Pill (活心丸) Attenuates Cardiac Fibrosis by Suppressing TGF-β1/Smad2/3 Pathway in Isoproterenol-Induced Heart Failure Rats[J]. Chinese Journal of Integrative Medicine, 2021,27(6):424-431.
Mei-zhong PENG, Mei-ling YANG, A-ling SHEN, et al. Huoxin Pill (活心丸) Attenuates Cardiac Fibrosis by Suppressing TGF-β1/Smad2/3 Pathway in Isoproterenol-Induced Heart Failure Rats[J]. Chinese Journal of Integrative Medicine, 2021,27(6):424-431.
Mei-zhong PENG, Mei-ling YANG, A-ling SHEN, 等. Huoxin Pill (活心丸) Attenuates Cardiac Fibrosis by Suppressing TGF-β1/Smad2/3 Pathway in Isoproterenol-Induced Heart Failure Rats[J]. Chinese Journal of Integrative Medicine, 2021,27(6):424-431. DOI: 10.1007/s11655-020-2862-8.
Mei-zhong PENG, Mei-ling YANG, A-ling SHEN, et al. Huoxin Pill (活心丸) Attenuates Cardiac Fibrosis by Suppressing TGF-β1/Smad2/3 Pathway in Isoproterenol-Induced Heart Failure Rats[J]. Chinese Journal of Integrative Medicine, 2021,27(6):424-431. DOI: 10.1007/s11655-020-2862-8.
Objective:
2
To evaluate the effects of Huoxin Pill (活心丸
HXP) on cardiac fibrosis and heart failure (HF) in isoproterenol (ISO)-induced HF rats.
Methods:
2
Thirty Wistar rats were randomly divided into 5 groups including control
HF
isosorbide mononitrate (ISMN)
HXP low (HXP-L)
and HXP high (HXP-H) groups (
n
=6 for each group) according to the complete randomization method. Rats were pretreated with ISMN (5 mg/kg daily)
low concentration of HXP (10 mg/kg daily) or high concentration of HXP (30 mg/kg daily) or equal volume of saline by intragastric administration for 1 week
followed by intraperitoneal injection of ISO (10 mg/kg
14 days)
and continually intragastric administrated with above medicines or saline for additional 6 weeks. The effects of HXP treatment on the cardiac function
heart weight index (HWI)
pathological changes
and collagen content were further assessed. Moreover
the role of HXP on activation of transforming growth factor-β1 (TGF-β1)/Smads pathway was further explored using immunohistochemistry (IHC) and Westernblot assay.
Results:
2
HXP treatment significantly alleviated the decrease of ejection fraction (EF) and fractional shortening (FS)
while decreased the elevation of left ventricular end-systolic volume (LVESV) in ISO-induced HF rats (
P
<
0.05). Moreover
HXP treatment obviously attenuated the increase of HWI and serum level of creatine kinase MB (CK-MB
P
<
0.05)
as well as pathological changes in ISO-induced HF rats. Further determination indicated that HXP treatment alleviated the elevation of collagen Ⅰ and collagen Ⅲ protein expression in cardiac tissues of ISO-induced HF rats. Furthermore
HXP treatment significantly down-regulated the increase of TGF-β1 and p-Smad2/3 protein expression in cardiac tissues of HF rats (
P
<
0.05)
while did not affect the expression of total Smad2/3.
Conclusions:
2
HXP attenuated heart failure and cardiac fibrosis in ISO-induced HF rats by suppression of TGF-β1/Smad2/3 pathway.
Huoxin Pillheart failurecardiac fibrosisisoproterenolTGF-β1/Smad2/3 pathway
BR Pagliaro, F Cannata, GG Stefanini, L Bolognese.Myocardial ischemia and coronary disease in heart failure.Heart Fail Rev 2020;25:53-65.
RV Shah, J Rong, MG Larson, A Yeri, O Ziegler, K Tanriverdi, et al. Associations of circulating extracellular RNAs with myocardial remodeling and heart failure. JAMA Cardiol 2018;3:871-876.
D Mozaffarian, EJ Benjamin, AS Go, DK Arnett, MJ Blaha, M Cushman, et al. Heart disease and stroke statistics—2015 update: a report from the American Heart Association.Circulation 2015;131:e329-e322.
D Levy, S Kenchaiah, MG Larson, EJ Benjamin, MJ Kupka, KK Ho, et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med 2002;347:1397-1402.
JL Januzzi, J Butler, E Fombu, A Maisel, K McCague, IL Piña, et al. Rationale and methods of the prospective study of biomarkers, symptom improvement, and ventricular remodeling during sacubitril/valsartan therapy for heart failure (PROVE-HF). Am Heart J 2018;199:130-136.
L Bacmeister, M Schwarzl, S Warnke, B Stoffers, S Blankenberg, D Westermann, et al. Inflammation and fibrosis in murine models of heart failure. Basic Res Cardiol 2019;114:19.
M Dobaczewski, M Bujak, N Li, C Gonzalez-Quesada, LH Mendoza, XF Wang, et al. Smad3 signaling critically regulates fibroblast phenotype and function in healing myocardial infarction. Circ Res 2010 6;107:418-428.
M Bujak, NG Frangogiannis. The role of TGF-beta signaling in myocardial infarction and cardiac remodeling. Cardiovasc Res 2007;74:184-195.
A Tandon, JC Tovey, A Sharma, R Gupta, RR Mohan.Role of transforming growth factor beta in corneal function, biology and pathology. Curr Mol Med 2010;10:565-578.
J Hao, H Ju, S Zhao, A Junaid, T Scammell-La Fleur, IM Dixon. Elevation of expression of Smads 2, 3, and 4, decorin and TGF-beta in the chronic phase of myocardial infarct scar healing. J Mol Cell Cardiol 1999;31:667-678.
M Ikeuchi, H Tsutsui, T Shiomi, H Matsusaka, S Matsushima, J Wen, et al. Inhibition of TGF-beta signaling exacerbates early cardiac dysfunction but prevents late remodeling after infarction. Cardiovasc Res 2004;64:526-535.
Z Zeng, Q Wang, X Yang, Y Ren, S Jiao, Q Zhu, et al.Qishen granule attenuates cardiac fibrosis by regulating TGF-β /Smad3 and GSK-3β pathway. Phytomedicine 2019;62:152949.
A Han, Y Lu, Q Zheng, J Zhang, Y Zhao, M Zhao, et al.Qiliqiangxin attenuates cardiac remodeling via inhibition of TGF-β1/Smad3 and NF-κB signaling pathways in a rat model of myocardial infarction. Cell Physiol Biochem 2018;45:1797-1806.
QW Wang, XF Yu, HL Xu, XZ Zhao, DY Sui. Ginsenoside Re improves isoproterenol-induced myocardial fibrosis and heart failure in rats. Evid Based Complement Alternat Med 2019;2019:3714508.
P Gong, Y Li, C Yao, H Guo, H Hwang, X Liu, et al.Traditional Chinese medicine on the treatment of coronary heart disease in recent 20 years. J Altern Complement Med 2017;23:659-666.
P Akila, L Asaikumar, L Vennila. Chlorogenic acid ameliorates isoproterenol-induced myocardial injury in rats by stabilizing mitochondrial and lysosomal enzymes.Biomed Pharmacother 2017;85:582-591.
S Rani, PK Sreenivasaiah, JO Kim, MY Lee, WS Kang, YS Kim, et al. Tauroursodeoxycholic acid (TUDCA) attenuates pressure overload-induced cardiac remodeling by reducing endoplasmic reticulum stress. PLoS One 2017;12:e0176071.
P Li, Q Song, T Liu, Z Wu, X Chu, X Zhang, et al. Inhibitory effect of cinobufagin on L-type Ca2+ currents, contractility, and Ca2+ homeostasis of isolated adult rat ventricular myocytes. Sci World J 2014;2014:496705.
X Wu, M Li, SQ Chen, S Li, F Guo. Pin1 facilitates isoproterenol-induced cardiac fibrosis and collagen deposition by promoting oxidative stress and activating the MEK1/2-ERK1/2 signal transduction pathway in rats. Int J Mol Med 2018;41:1573-1583.
AR Marks. Calcium cycling proteins and heart failure:mechanisms and therapeutics. J Clin Invest 2013;123:46-52.
LH Lu, C Li, QY Wang, Q Zhang, Y Zhang, H Meng, et al.Cardioprotective effects of Qishen Granule on sarcoplasmic reticulum Ca2+ handling in heart failure rats. Chin J Integr Med 2017;23:510-517.
YC Wang, DF Ma, P Jiang, YM Zhang, GF Zhou, JL Yang, et al. Guizhi Decoction inhibits cholinergic transdifferentiation by regulating imbalance of NGF and LIF in salt-sensitive hypertensive heart failure rats. Chin J Integr Med 2020;26:188-196.
H Yang, FF Zhang, XH Peng, DH Zhao, J Peng. Efficacy of medication directed by home-monitoring cardiac resynchronization therapy in chronic heart failure patients.Chin Med Sci J 2014;29:61-62.
L Li, J Hao, X Jiang, P Li, H Sen. Cardioprotective effects of ulinastatin against isoproterenol-induced chronic heart failure through the PI3K-Akt, p38 MAPK and NF-κB pathways. Mol Med Rep 2018;17:1354-1360.
JJ Wang, C Rau, R Avetisyan, S Ren, MC Romay, G Stolin, et al. Genetic dissection of cardiac remodeling in an isoproterenol-induced heart failure mouse model. PLoS Genet 2016;12:e1006038.
SS Mohamed, LA Ahmed, WA Attia, MM Khattab.Nicorandil enhances the efficacy of mesenchymal stem cell therapy in isoproterenol-induced heart failure in rats.Biochem Pharmacol 2015;98:403-411.
FD Siman, EA Silveira, AA Fernandes, I Stefanon, DV Vassallo, AS Padilha. Ouabain induces nitric oxide release by a PI3K/Akt-dependent pathway in isolated aortic rings from rats with heart failure. J Cardiovasc Pharmacol 2015;65:28-38.
JE Sanderson. New treatments for myocardial fibrosis.Cardiovasc Drugs Ther 2002;16:181-182.
DJ Lok, SI Lok, PW Bruggink-André de la Porte, E Badings, E Lipsic, J van Wijngaarden, et al. Galectin-3 is an independent marker for ventricular remodeling and mortality in patients with chronic heart failure. Clin Res Cardiol 2013;102:103-110.
A Biernacka, M Dobaczewski, NG Frangogiannis. TGF-β signaling in fibrosis. Growth Factors 2011;29:196-202.
PJ Lijnen, VV Petrov, RH Fagard. Induction of cardiac fibrosis by transforming growth factor-beta 1. Mol Genet Metab 2000;71:418-435.
P ten Dijke, HM Arthur. Extracellular control of TGF beta signalling in vascular development and disease. Nat Rev Mol Cell Biol 2007;8:857-869.
0
浏览量
2
Downloads
3
CSCD
关联资源
相关文章
相关作者
相关机构